Whole-body biodistribution, radiation absorbed dose and brain SPECT imaging with iodine-123-beta-CIT in healthy human subjects

Autor: Jp, Seibyl, Wallace E, Eo, Smith, Stabin M, Rm, Baldwin, Zoghbi S, Zea-Ponce Y, Gao Y, Wy, Zhang, John Neumeyer

Publikováno v: Europe PubMed Central

SPECT imaging with 123I-labeled methyl 3 beta-(4-iodophenyl)tropane-2 beta-carboxylate ([123I]beta-CIT) in nonhuman primates has shown brain striatal activity, which primarily reflects binding to the dopamine transporter. The biodistribution and calc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::ed55abfbfc10e7da1b03c92be6790253
https://pubmed.ncbi.nlm.nih.gov/7699474

α-Synuclein Seeding Amplification Assay: A Breakthrough in Diagnosing Parkinson Disease?

Autor: Seibyl JP; Institute for Neurodegenerative Disorders and Yale University School of Medicine, New Haven, Connecticut jpseibyl@seibyl.com.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2024 Feb 01; Vol. 65 (2), pp. 174-175. Date of Electronic Publication: 2024 Feb 01.

A Visual Interpretation Algorithm for Assessing Brain Tauopathy with ¹⁸ F-MK-6240 PET.

Autor: Seibyl JP; Institute for Neurodegenerative Disorders, New Haven, Connecticut; jpseibyl@seibyl.com.; Invicro, New Haven, Connecticut., DuBois JM; Biogen, Cambridge, Massachusetts., Racine A; Biogen, Cambridge, Massachusetts., Collins J; Biogen, Cambridge, Massachusetts., Guo Q; AbbVie, North Chicago, Illinois., Wooten D; Biogen, Cambridge, Massachusetts., Stage E; AbbVie, North Chicago, Illinois., Cheng D; Invicro, New Haven, Connecticut., Gunn RN; Invicro, New Haven, Connecticut., Porat L; Invicro, New Haven, Connecticut., Whittington A; Invicro, New Haven, Connecticut., Kuo PH; University of Arizona, Tucson, Arizona; and., Ichise M; National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan., Comley R; AbbVie, North Chicago, Illinois., Martarello L; Biogen, Cambridge, Massachusetts., Salinas C; Biogen, Cambridge, Massachusetts.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Mar; Vol. 64 (3), pp. 444-451. Date of Electronic Publication: 2022 Sep 29.

¹⁸ F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.

Autor: Messerschmidt K; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany; konstantin.messerschmidt@medizin.uni-leipzig.de., Barthel H; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany., Brendel M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany.; German Center for Neurodegenerative Diseases, Site Munich, Bonn, Germany.; Munich Cluster for Systems Neurology, Munich, Germany., Scherlach C; Department of Neuroradiology, Leipzig University Medical Center, Leipzig, Germany., Hoffmann KT; Department of Neuroradiology, Leipzig University Medical Center, Leipzig, Germany., Rauchmann BS; Department of Radiology, University Hospital of Munich, LMU Munich, Munich, Germany., Rullmann M; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany., Marek K; InviCRO LLC, Boston, Massachusetts., Villemagne VL; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania., Rumpf JJ; Department of Neurology, Leipzig University Medical Center, Leipzig, Germany., Saur D; Department of Neurology, Leipzig University Medical Center, Leipzig, Germany., Schroeter ML; Clinic for Cognitive Neurology, Leipzig University Medical Center, Leipzig, Germany., Schildan A; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany., Patt M; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany., Beyer L; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Song M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Palleis C; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Katzdobler S; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Fietzek UM; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Respondek G; Department of Neurology, Hannover Medical School, Hannover, Germany., Scheifele M; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Nitschmann A; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Zach C; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Barret O; InviCRO LLC, Boston, Massachusetts., Madonia J; InviCRO LLC, Boston, Massachusetts., Russell D; InviCRO LLC, Boston, Massachusetts., Stephens AW; Life Molecular Imaging GmbH, Berlin, Germany; and., Koglin N; Life Molecular Imaging GmbH, Berlin, Germany; and., Roeber S; Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany., Herms J; Center for Neuropathology and Prion Research, University Hospital of Munich, LMU Munich, Munich, Germany., Bötzel K; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Bartenstein P; Department of Nuclear Medicine, University Hospital of Munich, LMU Munich, Munich, Germany., Levin J; German Center for Neurodegenerative Diseases, Site Munich, Bonn, Germany.; Munich Cluster for Systems Neurology, Munich, Germany.; Department of Neurology, University Hospital of Munich, LMU Munich, Munich, Germany., Seibyl JP; InviCRO LLC, Boston, Massachusetts., Höglinger G; German Center for Neurodegenerative Diseases, Site Munich, Bonn, Germany.; Munich Cluster for Systems Neurology, Munich, Germany.; Department of Neurology, Hannover Medical School, Hannover, Germany., Classen J; Department of Neurology, Leipzig University Medical Center, Leipzig, Germany., Sabri O; Department of Nuclear Medicine, Leipzig University Medical Center, Leipzig, Germany.

Publikováno v: Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2022 Nov; Vol. 63 (11), pp. 1754-1760. Date of Electronic Publication: 2022 Apr 14.

Statistical Considerations in the Design of Clinical Trials Targeting Prodromal Parkinson Disease.

Autor: Macklin EA; From the Biostatistics Center (E.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Biostatistics (C.S.C., M.C.B.), College of Public Health, University of Iowa, Iowa City; and Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT. emacklin@mgh.harvard.edu., Coffey CS; From the Biostatistics Center (E.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Biostatistics (C.S.C., M.C.B.), College of Public Health, University of Iowa, Iowa City; and Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT., Brumm MC; From the Biostatistics Center (E.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Biostatistics (C.S.C., M.C.B.), College of Public Health, University of Iowa, Iowa City; and Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT., Seibyl JP; From the Biostatistics Center (E.A.M.), Massachusetts General Hospital and Harvard Medical School, Boston; Department of Biostatistics (C.S.C., M.C.B.), College of Public Health, University of Iowa, Iowa City; and Institute for Neurodegenerative Disorders (J.P.S.), New Haven, CT.

Publikováno v: Neurology [Neurology] 2022 Aug 16; Vol. 99 (7 Suppl 1), pp. 68-75.